id stringlengths 8 10 | pid stringlengths 10 12 | input stringlengths 1.56k 54.7k | output stringclasses 3
values |
|---|---|---|---|
619_nda-7 | 619_nda-7_0 | Q: Receiving Party may share some Confidential Information with some third-parties (including consultants, agents and professional advisors).
Text: EXHIBIT (d)(5)
MUTUAL NON-DISCLOSURE AGREEMENT
This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”), is by and between Bio... | Entailment |
619_nda-17 | 619_nda-17_0 | Q: Receiving Party may create a copy of some Confidential Information in some circumstances.
Text: EXHIBIT (d)(5)
MUTUAL NON-DISCLOSURE AGREEMENT
This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”), is by and between BioMarin Pharmaceutical Inc., a Delaware corporation... | Not mentioned |
619_nda-8 | 619_nda-8_0 | Q: Receiving Party shall notify Disclosing Party in case Receiving Party is required by law, regulation or judicial process to disclose any Confidential Information.
Text: EXHIBIT (d)(5)
MUTUAL NON-DISCLOSURE AGREEMENT
This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”... | Entailment |
619_nda-13 | 619_nda-13_0 | Q: Receiving Party may acquire information similar to Confidential Information from a third party.
Text: EXHIBIT (d)(5)
MUTUAL NON-DISCLOSURE AGREEMENT
This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”), is by and between BioMarin Pharmaceutical Inc., a Delaware corpo... | Entailment |
619_nda-5 | 619_nda-5_0 | Q: Receiving Party may share some Confidential Information with some of Receiving Party's employees.
Text: EXHIBIT (d)(5)
MUTUAL NON-DISCLOSURE AGREEMENT
This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”), is by and between BioMarin Pharmaceutical Inc., a Delaware cor... | Entailment |
619_nda-4 | 619_nda-4_0 | Q: Receiving Party shall not use any Confidential Information for any purpose other than the purposes stated in Agreement.
Text: EXHIBIT (d)(5)
MUTUAL NON-DISCLOSURE AGREEMENT
This Mutual Non-Disclosure Agreement (the “Agreement”), effective July 31, 2014 (the “Effective Date”), is by and between BioMarin Pharmaceutica... | Entailment |
620_nda-11 | 620_nda-11_0 | Q: Receiving Party shall not reverse engineer any objects which embody Disclosing Party's Confidential Information.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your... | Not mentioned |
620_nda-16 | 620_nda-16_0 | Q: Receiving Party shall destroy or return some Confidential Information upon the termination of Agreement.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your conside... | Not mentioned |
620_nda-15 | 620_nda-15_0 | Q: Agreement shall not grant Receiving Party any right to Confidential Information.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible neg... | Not mentioned |
620_nda-10 | 620_nda-10_0 | Q: Receiving Party shall not disclose the fact that Agreement was agreed or negotiated.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible... | Entailment |
620_nda-2 | 620_nda-2_0 | Q: Confidential Information shall only include technical information.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated busine... | Not mentioned |
620_nda-1 | 620_nda-1_0 | Q: All Confidential Information shall be expressly identified by the Disclosing Party.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible ... | Not mentioned |
620_nda-19 | 620_nda-19_0 | Q: Some obligations of Agreement may survive termination of Agreement.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated busin... | Entailment |
620_nda-12 | 620_nda-12_0 | Q: Receiving Party may independently develop information similar to Confidential Information.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a po... | Entailment |
620_nda-20 | 620_nda-20_0 | Q: Receiving Party may retain some Confidential Information even after the return or destruction of Confidential Information.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection... | Entailment |
620_nda-3 | 620_nda-3_0 | Q: Confidential Information may include verbally conveyed information.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negotiated busin... | Entailment |
620_nda-18 | 620_nda-18_0 | Q: Receiving Party shall not solicit some of Disclosing Party's representatives.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a possible negoti... | Entailment |
620_nda-7 | 620_nda-7_0 | Q: Receiving Party may share some Confidential Information with some third-parties (including consultants, agents and professional advisors).
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentleme... | Entailment |
620_nda-17 | 620_nda-17_0 | Q: Receiving Party may create a copy of some Confidential Information in some circumstances.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of a pos... | Not mentioned |
620_nda-8 | 620_nda-8_0 | Q: Receiving Party shall notify Disclosing Party in case Receiving Party is required by law, regulation or judicial process to disclose any Confidential Information.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Cou... | Entailment |
620_nda-13 | 620_nda-13_0 | Q: Receiving Party may acquire information similar to Confidential Information from a third party.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration of... | Entailment |
620_nda-5 | 620_nda-5_0 | Q: Receiving Party may share some Confidential Information with some of Receiving Party's employees.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection with your consideration ... | Entailment |
620_nda-4 | 620_nda-4_0 | Q: Receiving Party shall not use any Confidential Information for any purpose other than the purposes stated in Agreement.
Text: Exhibit (e)(2)
September 19, 2017
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, California 94949
Attention: Karah Parschauer, General Counsel
Ladies and Gentlemen:
In connection wi... | Entailment |
621_nda-11 | 621_nda-11_0 | Q: Receiving Party shall not reverse engineer any objects which embody Disclosing Party's Confidential Information.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of inform... | Not mentioned |
621_nda-16 | 621_nda-16_0 | Q: Receiving Party shall destroy or return some Confidential Information upon the termination of Agreement.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by... | Entailment |
621_nda-15 | 621_nda-15_0 | Q: Agreement shall not grant Receiving Party any right to Confidential Information.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Thera... | Entailment |
621_nda-10 | 621_nda-10_0 | Q: Receiving Party shall not disclose the fact that Agreement was agreed or negotiated.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark T... | Entailment |
621_nda-2 | 621_nda-2_0 | Q: Confidential Information shall only include technical information.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc.,... | Contradiction |
621_nda-1 | 621_nda-1_0 | Q: All Confidential Information shall be expressly identified by the Disclosing Party.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Th... | Entailment |
621_nda-19 | 621_nda-19_0 | Q: Some obligations of Agreement may survive termination of Agreement.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc.... | Entailment |
621_nda-12 | 621_nda-12_0 | Q: Receiving Party may independently develop information similar to Confidential Information.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between S... | Entailment |
621_nda-20 | 621_nda-20_0 | Q: Receiving Party may retain some Confidential Information even after the return or destruction of Confidential Information.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure... | Entailment |
621_nda-3 | 621_nda-3_0 | Q: Confidential Information may include verbally conveyed information.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc.... | Entailment |
621_nda-18 | 621_nda-18_0 | Q: Receiving Party shall not solicit some of Disclosing Party's representatives.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeu... | Not mentioned |
621_nda-7 | 621_nda-7_0 | Q: Receiving Party may share some Confidential Information with some third-parties (including consultants, agents and professional advisors).
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), govern... | Entailment |
621_nda-17 | 621_nda-17_0 | Q: Receiving Party may create a copy of some Confidential Information in some circumstances.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Sp... | Entailment |
621_nda-8 | 621_nda-8_0 | Q: Receiving Party shall notify Disclosing Party in case Receiving Party is required by law, regulation or judicial process to disclose any Confidential Information.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “... | Entailment |
621_nda-13 | 621_nda-13_0 | Q: Receiving Party may acquire information similar to Confidential Information from a third party.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and betw... | Entailment |
621_nda-5 | 621_nda-5_0 | Q: Receiving Party may share some Confidential Information with some of Receiving Party's employees.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and be... | Entailment |
621_nda-4 | 621_nda-4_0 | Q: Receiving Party shall not use any Confidential Information for any purpose other than the purposes stated in Agreement.
Text: Exhibit 99.(d)(2)
MUTUAL NON-DISCLOSURE AGREEMENT
THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of... | Entailment |
622_nda-11 | 622_nda-11_0 | Q: Receiving Party shall not reverse engineer any objects which embody Disclosing Party's Confidential Information.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered ... | Not mentioned |
622_nda-16 | 622_nda-16_0 | Q: Receiving Party shall destroy or return some Confidential Information upon the termination of Agreement.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into eff... | Not mentioned |
622_nda-15 | 622_nda-15_0 | Q: Agreement shall not grant Receiving Party any right to Confidential Information.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 20... | Not mentioned |
622_nda-10 | 622_nda-10_0 | Q: Receiving Party shall not disclose the fact that Agreement was agreed or negotiated.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27... | Entailment |
622_nda-2 | 622_nda-2_0 | Q: Confidential Information shall only include technical information.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effec... | Contradiction |
622_nda-1 | 622_nda-1_0 | Q: All Confidential Information shall be expressly identified by the Disclosing Party.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27,... | Contradiction |
622_nda-19 | 622_nda-19_0 | Q: Some obligations of Agreement may survive termination of Agreement.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effe... | Entailment |
622_nda-12 | 622_nda-12_0 | Q: Receiving Party may independently develop information similar to Confidential Information.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of J... | Entailment |
622_nda-20 | 622_nda-20_0 | Q: Receiving Party may retain some Confidential Information even after the return or destruction of Confidential Information.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made an... | Not mentioned |
622_nda-3 | 622_nda-3_0 | Q: Confidential Information may include verbally conveyed information.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 (the “Effe... | Entailment |
622_nda-18 | 622_nda-18_0 | Q: Receiving Party shall not solicit some of Disclosing Party's representatives.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of June 27, 2013 ... | Entailment |
622_nda-7 | 622_nda-7_0 | Q: Receiving Party may share some Confidential Information with some third-parties (including consultants, agents and professional advisors).
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreem... | Entailment |
622_nda-17 | 622_nda-17_0 | Q: Receiving Party may create a copy of some Confidential Information in some circumstances.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as of Ju... | Entailment |
622_nda-8 | 622_nda-8_0 | Q: Receiving Party shall notify Disclosing Party in case Receiving Party is required by law, regulation or judicial process to disclose any Confidential Information.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION... | Entailment |
622_nda-13 | 622_nda-13_0 | Q: Receiving Party may acquire information similar to Confidential Information from a third party.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective as... | Entailment |
622_nda-5 | 622_nda-5_0 | Q: Receiving Party may share some Confidential Information with some of Receiving Party's employees.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and entered into effective ... | Entailment |
622_nda-4 | 622_nda-4_0 | Q: Receiving Party shall not use any Confidential Information for any purpose other than the purposes stated in Agreement.
Text: Exhibit 10.16
AMENDED AND RESTATED
SERVICES, RESELLER AND NON-COMPETITION AGREEMENT
THIS AMENDED AND RESTATED SERVICES, RESELLER AND NON-COMPETITION AGREEMENT (this “Agreement”) is made and e... | Entailment |
623_nda-11 | 623_nda-11_0 | Q: Receiving Party shall not reverse engineer any objects which embody Disclosing Party's Confidential Information.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together w... | Not mentioned |
623_nda-16 | 623_nda-16_0 | Q: Receiving Party shall destroy or return some Confidential Information upon the termination of Agreement.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alli... | Not mentioned |
623_nda-15 | 623_nda-15_0 | Q: Agreement shall not grant Receiving Party any right to Confidential Information.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entiti... | Entailment |
623_nda-10 | 623_nda-10_0 | Q: Receiving Party shall not disclose the fact that Agreement was agreed or negotiated.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua En... | Not mentioned |
623_nda-2 | 623_nda-2_0 | Q: Confidential Information shall only include technical information.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesapea... | Contradiction |
623_nda-1 | 623_nda-1_0 | Q: All Confidential Information shall be expressly identified by the Disclosing Party.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Ent... | Not mentioned |
623_nda-19 | 623_nda-19_0 | Q: Some obligations of Agreement may survive termination of Agreement.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesape... | Not mentioned |
623_nda-12 | 623_nda-12_0 | Q: Receiving Party may independently develop information similar to Confidential Information.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alli... | Entailment |
623_nda-20 | 623_nda-20_0 | Q: Receiving Party may retain some Confidential Information even after the return or destruction of Confidential Information.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and ... | Not mentioned |
623_nda-3 | 623_nda-3_0 | Q: Confidential Information may include verbally conveyed information.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”), Chesape... | Entailment |
623_nda-18 | 623_nda-18_0 | Q: Receiving Party shall not solicit some of Disclosing Party's representatives.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliqua Entities”... | Entailment |
623_nda-7 | 623_nda-7_0 | Q: Receiving Party may share some Confidential Information with some third-parties (including consultants, agents and professional advisors).
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqu... | Contradiction |
623_nda-17 | 623_nda-17_0 | Q: Receiving Party may create a copy of some Confidential Information in some circumstances.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the “Alliq... | Not mentioned |
623_nda-8 | 623_nda-8_0 | Q: Receiving Party shall notify Disclosing Party in case Receiving Party is required by law, regulation or judicial process to disclose any Confidential Information.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-ow... | Entailment |
623_nda-13 | 623_nda-13_0 | Q: Receiving Party may acquire information similar to Confidential Information from a third party.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, the ... | Entailment |
623_nda-5 | 623_nda-5_0 | Q: Receiving Party may share some Confidential Information with some of Receiving Party's employees.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and together with Alliqua, th... | Contradiction |
623_nda-4 | 623_nda-4_0 | Q: Receiving Party shall not use any Confidential Information for any purpose other than the purposes stated in Agreement.
Text: Exhibit 10.3
NON-COMPETITION AGREEMENT
WHEREAS, Alliqua BioMedical, Inc. (“Alliqua”), Alliqua Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of Alliqua (“Parent” and tog... | Entailment |
624_nda-11 | 624_nda-11_0 | Q: Receiving Party shall not reverse engineer any objects which embody Disclosing Party's Confidential Information.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and ... | Not mentioned |
624_nda-16 | 624_nda-16_0 | Q: Receiving Party shall destroy or return some Confidential Information upon the termination of Agreement.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lill... | Not mentioned |
624_nda-15 | 624_nda-15_0 | Q: Agreement shall not grant Receiving Party any right to Confidential Information.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indian... | Entailment |
624_nda-10 | 624_nda-10_0 | Q: Receiving Party shall not disclose the fact that Agreement was agreed or negotiated.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an In... | Entailment |
624_nda-2 | 624_nda-2_0 | Q: Confidential Information shall only include technical information.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation ... | Contradiction |
624_nda-1 | 624_nda-1_0 | Q: All Confidential Information shall be expressly identified by the Disclosing Party.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Ind... | Not mentioned |
624_nda-19 | 624_nda-19_0 | Q: Some obligations of Agreement may survive termination of Agreement.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation... | Entailment |
624_nda-12 | 624_nda-12_0 | Q: Receiving Party may independently develop information similar to Confidential Information.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company,... | Entailment |
624_nda-20 | 624_nda-20_0 | Q: Receiving Party may retain some Confidential Information even after the return or destruction of Confidential Information.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Sell... | Entailment |
624_nda-3 | 624_nda-3_0 | Q: Confidential Information may include verbally conveyed information.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana corporation... | Entailment |
624_nda-18 | 624_nda-18_0 | Q: Receiving Party shall not solicit some of Disclosing Party's representatives.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, an Indiana c... | Entailment |
624_nda-7 | 624_nda-7_0 | Q: Receiving Party may share some Confidential Information with some third-parties (including consultants, agents and professional advisors).
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware co... | Entailment |
624_nda-17 | 624_nda-17_0 | Q: Receiving Party may create a copy of some Confidential Information in some circumstances.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Company, ... | Not mentioned |
624_nda-8 | 624_nda-8_0 | Q: Receiving Party shall notify Disclosing Party in case Receiving Party is required by law, regulation or judicial process to disclose any Confidential Information.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Bioscien... | Entailment |
624_nda-13 | 624_nda-13_0 | Q: Receiving Party may acquire information similar to Confidential Information from a third party.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and Com... | Entailment |
624_nda-5 | 624_nda-5_0 | Q: Receiving Party may share some Confidential Information with some of Receiving Party's employees.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”), and Eli Lilly and C... | Entailment |
624_nda-4 | 624_nda-4_0 | Q: Receiving Party shall not use any Confidential Information for any purpose other than the purposes stated in Agreement.
Text: Exhibit (d)(3)
NON-DISCLOSURE AGREEMENT
This NON-DISCLOSURE AGREEMENT (“Agreement”) is being entered into as of March 19, 2018 between ARMO Biosciences, Inc., a Delaware corporation (“Seller”... | Entailment |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.